NASDAQ:ALXO

ALX Oncology Competitors

$56.73
+2.29 (+4.21 %)
(As of 04/21/2021 12:00 PM ET)
Add
Compare
Today's Range
$53.91
Now: $56.73
$56.93
50-Day Range
$56.46
MA: $69.80
$87.68
52-Week Range
$28.01
Now: $56.73
$117.45
Volume3,192 shs
Average Volume237,626 shs
Market Capitalization$2.28 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

ALX Oncology (NASDAQ:ALXO) Vs. BBIO, MRTX, ARWR, RARE, GWPH, and ASND

Should you be buying ALXO stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to ALX Oncology, including BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), Arrowhead Pharmaceuticals (ARWR), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH), and Ascendis Pharma A/S (ASND).

ALX Oncology (NASDAQ:ALXO) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares ALX Oncology and BridgeBio Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALX OncologyN/AN/AN/AN/AN/A
BridgeBio Pharma$40.56 million201.29$-260,590,000.00($2.48)-22.10

ALX Oncology has higher earnings, but lower revenue than BridgeBio Pharma.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for ALX Oncology and BridgeBio Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ALX Oncology00703.00
BridgeBio Pharma01902.90

ALX Oncology currently has a consensus price target of $90.6667, suggesting a potential upside of 61.70%. BridgeBio Pharma has a consensus price target of $72.8889, suggesting a potential upside of 33.13%. Given ALX Oncology's stronger consensus rating and higher probable upside, equities research analysts clearly believe ALX Oncology is more favorable than BridgeBio Pharma.

Profitability

This table compares ALX Oncology and BridgeBio Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ALX OncologyN/AN/AN/A
BridgeBio PharmaN/A-109.88%-48.54%

Insider and Institutional Ownership

73.5% of ALX Oncology shares are held by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are held by institutional investors. 40.3% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ALX Oncology (NASDAQ:ALXO) and Mirati Therapeutics (NASDAQ:MRTX) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares ALX Oncology and Mirati Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALX OncologyN/AN/AN/AN/AN/A
Mirati Therapeutics$3.34 million2,387.07$-213,260,000.00($5.69)-27.67

ALX Oncology has higher earnings, but lower revenue than Mirati Therapeutics.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for ALX Oncology and Mirati Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ALX Oncology00703.00
Mirati Therapeutics151002.56

ALX Oncology currently has a consensus price target of $90.6667, suggesting a potential upside of 61.70%. Mirati Therapeutics has a consensus price target of $218.5714, suggesting a potential upside of 38.08%. Given ALX Oncology's stronger consensus rating and higher probable upside, equities research analysts clearly believe ALX Oncology is more favorable than Mirati Therapeutics.

Profitability

This table compares ALX Oncology and Mirati Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ALX OncologyN/AN/AN/A
Mirati TherapeuticsN/A-60.01%-54.21%

Insider and Institutional Ownership

73.5% of ALX Oncology shares are held by institutional investors. Comparatively, 94.9% of Mirati Therapeutics shares are held by institutional investors. 4.1% of Mirati Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ALX Oncology (NASDAQ:ALXO) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Insider and Institutional Ownership

73.5% of ALX Oncology shares are held by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for ALX Oncology and Arrowhead Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ALX Oncology00703.00
Arrowhead Pharmaceuticals021002.83

ALX Oncology currently has a consensus price target of $90.6667, suggesting a potential upside of 61.70%. Arrowhead Pharmaceuticals has a consensus price target of $85.3077, suggesting a potential upside of 25.84%. Given ALX Oncology's stronger consensus rating and higher probable upside, equities research analysts clearly believe ALX Oncology is more favorable than Arrowhead Pharmaceuticals.

Profitability

This table compares ALX Oncology and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ALX OncologyN/AN/AN/A
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%

Earnings and Valuation

This table compares ALX Oncology and Arrowhead Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALX OncologyN/AN/AN/AN/AN/A
Arrowhead Pharmaceuticals$87.99 million80.74$-84,550,000.00($0.84)-81.49

ALX Oncology has higher earnings, but lower revenue than Arrowhead Pharmaceuticals.

Summary

ALX Oncology beats Arrowhead Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and ALX Oncology (NASDAQ:ALXO) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

73.5% of ALX Oncology shares are owned by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Ultragenyx Pharmaceutical and ALX Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%
ALX OncologyN/AN/AN/A

Earnings and Valuation

This table compares Ultragenyx Pharmaceutical and ALX Oncology's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$103.71 million69.57$-402,730,000.00($7.36)-14.64
ALX OncologyN/AN/AN/AN/AN/A

ALX Oncology has lower revenue, but higher earnings than Ultragenyx Pharmaceutical.

Analyst Recommendations

This is a summary of recent recommendations for Ultragenyx Pharmaceutical and ALX Oncology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ultragenyx Pharmaceutical06802.57
ALX Oncology00703.00

Ultragenyx Pharmaceutical presently has a consensus target price of $136.4667, suggesting a potential upside of 27.86%. ALX Oncology has a consensus target price of $90.6667, suggesting a potential upside of 61.70%. Given ALX Oncology's stronger consensus rating and higher probable upside, analysts plainly believe ALX Oncology is more favorable than Ultragenyx Pharmaceutical.

Summary

ALX Oncology beats Ultragenyx Pharmaceutical on 6 of the 9 factors compared between the two stocks.

ALX Oncology (NASDAQ:ALXO) and GW Pharmaceuticals (NASDAQ:GWPH) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Analyst Recommendations

This is a breakdown of current ratings and price targets for ALX Oncology and GW Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ALX Oncology00703.00
GW Pharmaceuticals010402.29

ALX Oncology currently has a consensus price target of $90.6667, suggesting a potential upside of 61.70%. GW Pharmaceuticals has a consensus price target of $204.0909, suggesting a potential downside of 6.54%. Given ALX Oncology's stronger consensus rating and higher possible upside, research analysts plainly believe ALX Oncology is more favorable than GW Pharmaceuticals.

Earnings & Valuation

This table compares ALX Oncology and GW Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALX OncologyN/AN/AN/AN/AN/A
GW Pharmaceuticals$311.33 million21.99$-9,020,000.00($0.24)-909.96

ALX Oncology has higher earnings, but lower revenue than GW Pharmaceuticals.

Profitability

This table compares ALX Oncology and GW Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ALX OncologyN/AN/AN/A
GW Pharmaceuticals-11.05%-7.46%-6.13%

Institutional & Insider Ownership

73.5% of ALX Oncology shares are held by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are held by institutional investors. 3.1% of GW Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

ALX Oncology beats GW Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

ALX Oncology (NASDAQ:ALXO) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.

Earnings & Valuation

This table compares ALX Oncology and Ascendis Pharma A/S's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALX OncologyN/AN/AN/AN/AN/A
Ascendis Pharma A/S$14.98 million445.43$-244,180,000.00($5.25)-23.65

ALX Oncology has higher earnings, but lower revenue than Ascendis Pharma A/S.

Analyst Recommendations

This is a breakdown of recent ratings for ALX Oncology and Ascendis Pharma A/S, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ALX Oncology00703.00
Ascendis Pharma A/S011002.91

ALX Oncology presently has a consensus target price of $90.6667, indicating a potential upside of 61.70%. Ascendis Pharma A/S has a consensus target price of $192.2222, indicating a potential upside of 55.12%. Given ALX Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe ALX Oncology is more favorable than Ascendis Pharma A/S.

Institutional and Insider Ownership

73.5% of ALX Oncology shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares ALX Oncology and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ALX OncologyN/AN/AN/A
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%

Summary

ALX Oncology beats Ascendis Pharma A/S on 6 of the 9 factors compared between the two stocks.


ALX Oncology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.81+1.3%$8.27 billion$40.56 million-16.07
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$157.46+1.0%$7.89 billion$3.34 million-20.45
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$68.45+0.5%$7.07 billion$87.99 million-81.49
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.6$107.77+2.6%$7.03 billion$103.71 million-24.55Analyst Report
Insider Selling
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.39+0.0%$6.85 billion$311.33 million-126.97News Coverage
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$124.14+0.7%$6.72 billion$14.98 million-15.12Unusual Options Activity
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.46+0.7%$5.80 billion$1.12 billion86.38Analyst Report
Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.54+0.3%$5.66 billion$380.83 million-9.15Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$40.56+1.5%$5.62 billion$150,000.00-19.13Analyst Report
Analyst Revision
News Coverage
Gap Up
Perrigo logo
PRGO
Perrigo
2.3$42.53+1.1%$5.62 billion$4.84 billion-708.72Dividend Announcement
Allakos logo
ALLK
Allakos
1.7$105.21+1.0%$5.57 billionN/A-38.40
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$93.03+0.5%$5.37 billion$66.51 million17.16Analyst Report
Galapagos logo
GLPG
Galapagos
1.3$82.66+3.6%$5.22 billion$1.00 billion-12.52Analyst Report
Gap Down
Schrödinger logo
SDGR
Schrödinger
1.5$71.94+2.7%$4.90 billion$85.54 million0.00
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.83+1.6%$4.57 billionN/A-6.10Analyst Report
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$72.75+1.0%$4.29 billion$6.87 million-7.03Analyst Report
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.31+1.1%$4.22 billion$204.89 million-36.64
I-Mab logo
IMAB
I-Mab
1.4$55.63+2.1%$4.09 billion$4.31 million-1.92
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.26+0.7%$4.03 billion$806.43 million-9.53Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.95+1.3%$3.89 billion$117.91 million-11.15
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.82+0.4%$3.70 billionN/A-6.18
LEGN
Legend Biotech
1.2$27.23+1.9%$3.55 billion$64.39 million0.00Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$65.54+0.1%$3.52 billion$1.11 billion21.07News Coverage
Gap Up
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$72.47+1.3%$3.50 billionN/A-20.65
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$41.02+3.2%$3.50 billionN/A0.00Increase in Short Interest
News Coverage
Gap Up
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.48+3.4%$3.43 billion$114.62 million-7.85
Insmed logo
INSM
Insmed
1.2$33.55+3.7%$3.34 billion$136.47 million-12.90
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.25+2.1%$3.33 billion$339.08 million-12.35Analyst Revision
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$45.81+1.1%$3.26 billion$306.98 million-6.55
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.79+1.7%$3.23 billion$26.52 million-8.00Unusual Options Activity
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$20.38+1.1%$3.21 billion$1.17 billion-44.30Insider Selling
Analyst Revision
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$45.50+0.5%$3.16 billion$36.13 million-67.91
Arvinas logo
ARVN
Arvinas
1.5$65.06+4.8%$3.03 billion$42.98 million-25.41Upcoming Earnings
Analyst Report
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.70+0.9%$2.96 billion$80.43 million108.10
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$108.36+0.3%$2.92 billionN/A-53.91News Coverage
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$76.63+0.9%$2.91 billion$644.77 million-10.93
OPKO Health logo
OPK
OPKO Health
1.9$4.26+3.1%$2.77 billion$901.90 million-23.67
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$64.44+2.8%$2.75 billion$421.03 million22.69News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.90+0.0%$2.65 billion$25 million-9.18Analyst Revision
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.78+1.1%$2.64 billion$306.49 million25.60
Organogenesis logo
ORGO
Organogenesis
1.0$21.05+2.6%$2.62 billion$260.98 million-350.83News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$42.56+0.6%$2.61 billionN/A-23.38
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.82+0.4%$2.59 billion$182.24 million-8.54Analyst Upgrade
Insider Selling
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$42.18+2.2%$2.57 billion$2.11 million-9.13Analyst Report
News Coverage
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$29.52+3.5%$2.47 billion$60,000.00-9.17Analyst Revision
News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$148.40+1.1%$2.44 billion$120.28 million-149.90Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.2$41.72+0.4%$2.41 billion$156.70 million-29.80
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$29.23+4.2%$2.32 billion$23.90 million-18.16Analyst Report
Insider Selling
Analyst Revision
News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.8$33.23+3.9%$2.26 billion$15 million-17.40
Cryoport logo
CYRX
Cryoport
1.7$51.75+4.1%$2.26 billion$33.94 million-89.22
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.